ACOG Unequivocally Supports ACIP’s Recommendation Approving Use of Maternal RSV Vaccine in Pregnancy

Washington, D.C.—The following is a statement from Christopher M. Zahn MD, FACOG, interim CEO of the American College of Obstetricians and Gynecologists (ACOG):

“ACOG unequivocally supports ACIP’s recommendation for the use of the maternal RSV vaccine in pregnancy during 32 through 36 weeks gestation using seasonal administration. The national and global burden of RSV disease demonstrates how critical it is to prevent this virus in infants. ACOG believes the maternal RSV vaccine is efficacious and it is necessary that parents have this option to protect their newborns from RSV after birth. ACOG is currently making updates to its clinical guidance that will be released in the coming days.”